Table 1.

Overview of the included studies in the meta-analysis

StudyPeriodCountryABO-incompatibleABO compatibleControlsDesensitizationInductionFollow-Up (mo)
Ashimine et al. (16)2005–09Japan51228consecutiveDFPPall: BASABOi: 36
ABOi with titer>8: RTXABOc: 52
2×200 mg
Barnett et al. (34)2005–11England62167consecutive>64: IAall: BASABOi: 26
16–64: DFPPABOi with titer≥8: RTXABOc: 33
≤8: none375 mg/m2 (n=2 ABOi: ATZ)
<2008: IVIG
Becker et al. (32)2005–13Germany3486MatchedIA with IVIGall: BASABOi: 22
ABOi: RTX 375 mg/m2ABOc: 20
Naciri Bennani et al. (35)2011–15France4444matched≥128: DFPP and IAall: DSA or PRA>25%: ATGABOi: 6
32–64: IAno DSA and PRA≤25%: BASABOc: 6
8–16: PEABOi: RTX 375 mg/m2
≤4 none
Bentall et al. (36)1999–2006United States73652consecutivePE with IVIGall: ATGABOi: 67
ABOc: 73
Flint et al. (37)2005–08Australia3752matchedPEall: BASABOi: 26
<2008: IVIGABOc: 22
Genberg et al. (1)2001–05Sweden1530matchedIA with IVIGABOc: noneABOi: 41
ABOi: RTX 375 mg/m2ABOc 48
Habicht et al. (38)2007–09Germany2147consecutiveIAall: BASABOi: 17
ABOi: RTX 375 mg/m2ABOc: 15
Hatakeyama et al. (6)2006–13Japan1329consecutiveDFPPall: BASABOi: 28
ABOi: RTX 100 mg/m2ABOc: 37
Hwang et al. (39)2009–11Korea35138matchedPE with IVIGall: BASABOi: 24
ABOi: RTX 100–375 mg/m2ABOc: 24
Iwai et al. (40)2001–14Japan416consecutiveDFPP or PEall: BASABOi: 39
ABOi: RTX 150 mg/m2ABOc: 38
Jha et al. (41)2011–14India20669consecutive5 pts: PE with IVIGABOc:ABOi: 10
12 pts: DFPP55% BAS, 5% ATG, 40% noneABOc: 17
3 pts: noneABOi: BAS and RTX 200 mg
Kauke et al. (42)2007–12Germany2652matchedIAABOc:ABOi: 12
PRA>5%: ATG and BASABOc:12
PRA≤5%: none
ABOi: ATG and RTX
Kim et al. (43)2010–16Korea71726consecutivePE and IVIGall: BASABOi: 27
ABOi: RTX 200 mgABOc: 42
Kwon et al. (44)2012–15Korea234600consecutivePEall: BASABOi: 36
ABOi: RTX (n=67: 500 mg;ABOc: 36
n=167: 200 mg)
Lee et al. (45)2010–14Korea97118consecutivePEall: BASABOi: 34
>128: IVIGABOi: RTXABOc: 36
≥128: 375 mg/m2
<128: 200 mg RTX
Melexopoulou et al. (46)2005–13Greece3030matchedIA or DFPPall: BAS or daclizumabABOi: 74
ABOi: RTX 375 mg/m2ABOc: 78
Okumi et al. (7)2005–13Japan144333consecutiveDFPPall: BASABOi: 48
ABOi: RTX 200 mgABOc: 56
Park et al. (47)2011–13Korea1121consecutiveDFPP and once PEall: BASABOi: 15
ABOi: RTX 200 mgABOc: 15
Sanchez-Escuredo et al. (48)2011–13Spain30146consecutivePE or IAall: BAS or ATG depending on immunologic riskABOi: 21
ABOi: RTX 2×200 mgABOc: 21
Schachtner et al. (4)2005–12Germany3562matchedIA, IVIGall: BASABOi: 42
ABOi: RTX 375 mg/m2ABOc: 37
Shin et al. (8)2009–12Korea73396consecutivePEall: BASABOi: 39
ABOi: RTX 500 or 200 mgABOc: 46
Subramanian et al. (9)2007–12United States1845matchedPE and IVIGall: ATGABOi: 29
ABOi: RTX 200 mgABOc: 29
Van Agteren (49)2006–12Netherlands50100matchedIA and IVIGABOc: BASABOi: 38
ABOi: RTX 375 mg/m2ABOc: 38
Yokoyama et al. (50)2008–13Japan2150consecutivePEall: BASABOi: 12
ABOi: RTXABOc: 12
Zschiedrich et al. (5)2004–14Germany97106consecutiveIAall: BASABOi: 58
ABOi: RTX 375 mg/m2ABOc: 48
Total13464943
  • ABOi, ABO-incompatible; ABOc, ABO-compatible; DFPP, double-filtration plasmapheresis; BAS, basiliximab; RTX, rituximab; IA, immunoadsorption; IVIG, intravenous immunoglobulin; ATZ, alemtuzumab; DSA, donor-specific antibodies; PRA, panel-reactive antibodies; ATG, anti-thymoglobulin; PE, plasma exchange.